Interestingly, several peptides with different degrees of co-agonism for the glucagon and GLP-1 receptors were recently discovered [35], and are currently in clinical evaluation for the treatment of obesity and diabetes [115,118]. This evidence concerns the gene GLP1R and diabetes mellitus.